Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

Novo Nordisk stock fell after Morgan Stanley said Ozempic and Wegovy prescription growth is stagnating, and recommended ...

India embraces GLP-1 medications as a major advance in diabetes and obesity care. Experts warn these drugs require medical ...

Semaglutide appears to provide a greater cardiovascular benefit vs dulaglutide in older T2D patients with ASCVD.

Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs.

Anthropic is significantly expanding its global workforce, planning to triple international employees by 2025 and hire ...

As India grapples with a surge in lifestyle-related illnesses, the approval of Ozempic marks more than just a new diabetes ...

Should the weight-loss pioneers be bracing for more lean years, then? Not necessarily. For although being first did not ...

Novo Nordisk is looking into whether the active ingredient in Ozempic and Wegovy can help Alzheimer’s patients. It could have ...

Novo Nordisk was downgraded to underweight by Morgan Stanley. Morgan Stanley analysts say a trial to test whether Novo Nordisk's blockbuster weight-loss drug also will work against Alzheimer's is ...

Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss ...

Morgan Stanley cut its rating on Novo Nordisk to Underweight from Equal-weight and lowered its price target to DKr 300 from DKr 380, citing “tough path ahead” for the drugmaker amid slowing ...